|
1
|
Liebs S, Keilholz U, Kehler I, Schweiger
C, Hayback J and Nonnenmacher A: Detection of mutations in
circulating cell-free DNA in relation to disease stage in
colorectal cancer. Cancer Med. 8:3761–3769. 2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Lei L, Zhao X, Liu S, Cao Q, Yan B and
Yang J: MicroRNA-3607 inhibits the tumorigenesis of colorectal
cancer by targeting DDI2 and regulating the DNA damage repair
pathway. Apoptosis. 24:662–672. 2019.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Wang Q, Wei J, Wang C, Zhang T, Huang D,
Wei F, He F, Cai W, Yang P, Zeng S, et al: Gambogic acid reverses
oxaliplatin resistance in colorectal cancer by increasing
intracellular platinum levels. Oncol Lett. 16:2366–2372.
2018.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Chibaudel B, Tournigand C, Bonnetain F,
Maindrault-Goebel F, Lledo G, André T, Larsen AK, Bengrine-Lefevre
L, Louvet C and de Gramont A: Platinum-sensitivity in metastatic
colorectal cancer: Towards a definition. Eur J Cancer.
49:3813–3820. 2013.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Huang CY, Chiang SF, Chen WT, Ke TW, Chen
TW, You YS, Lin CY, Chao KSC and Huang CY: HMGB1 promotes
ERK-mediated mitochondrial Drp1 phosphorylation for chemoresistance
through RAGE in colorectal cancer. Cell Death Dis.
9(1004)2018.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Ren J, Ding L, Zhang D, Shi G, Xu Q, Shen
S, Wang Y, Wang T and Hou Y: Carcinoma-associated fibroblasts
promote the stemness and chemoresistance of colorectal cancer by
transferring exosomal lncRNA H19. Theranostics. 8:3932–3948.
2018.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Zhang Z, Feng L, Liu P and Duan W: ANRIL
promotes chemoresistance via disturbing expression of ABCC1 by
regulating the expression of Let-7a in colorectal cancer. Biosci
Rep. 38(pii: BSR20180620)2018.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Gupta P, Sata TN, Yadav AK, Mishra A, Vats
N, Hossain MM, Sanal MG and Venugopal SK: TGF-β induces liver
fibrosis via miRNA-181a-mediated down regulation of augmenter of
liver regeneration in hepatic stellate cells. PLoS One.
14(e0214534)2019.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Huerta-Zavala ML, Lopez-Castillejos ES,
Requenez-Contreras JL, Granados-Riveron JT and Aquino-Jarquin G: A
single miRNA and miRNA sponge expression system for efficient
modulation of miR-223 availability in mammalian cells. J Gene Med.
21(e3100)2019.PubMed/NCBI View
Article : Google Scholar
|
|
10
|
Wu T, Cao Y, Yang Y and Zhang X, Wang S,
Xu LP and Zhang X: A three-dimensional DNA walking machine for the
ultrasensitive dual-modal detection of miRNA using a fluorometer
and personal glucose meter. Nanoscale. 11:11279–11284.
2019.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Powrozek T, Brzozowska A, Mazurek M, Mlak
R, Sobieszek G and Malecka-Massalska T: Combined analysis of
miRNA-181a with phase angle derived from bioelectrical impedance
predicts radiotherapy-induced changes in body composition and
survival of male patients with head and neck cancer. Head Neck.
41:3247–3257. 2019.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Vos PD, Leedman PJ, Filipovska A and
Rackham O: Modulation of miRNA function by natural and synthetic
RNA-binding proteins in cancer. Cell Mol Life Sci. 76:3745–3752.
2019.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Xie W, Sun F, Chen L and Cao X: miR-96
promotes breast cancer metastasis by suppressing MTSS1. Oncol Lett.
15:3464–3471. 2018.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Bao YH, Wang Y, Liu Y, Wang S and Wu B:
MiR-96 expression in prostate cancer and its effect on the target
gene regulation. Eur Rev Med Pharmacol Sci. 21:4548–4556.
2017.PubMed/NCBI
|
|
15
|
Hong Y, Liang H, Uzair Ur Rehman, Wang Y,
Zhang W, Zhou Y, Chen S, Yu M, Cui S, Liu M, et al: miR-96 promotes
cell proliferation, migration and invasion by targeting PTPN9 in
breast cancer. Sci Rep. 6(37421)2016.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Wu L, Pu X, Wang Q, Cao J, Xu F, Xu LI and
Li K: miR-96 induces cisplatin chemoresistance in non-small cell
lung cancer cells by downregulating SAMD9. Oncol Lett. 11:945–952.
2016.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Rapti SM, Kontos CK, Papadopoulos IN and
Scorilas A: High miR-96 levels in colorectal adenocarcinoma predict
poor prognosis, particularly in patients without distant metastasis
at the time of initial diagnosis. Tumour Biol. 37:11815–11824.
2016.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Ress AL, Stiegelbauer V, Winter E,
Schwarzenbacher D, Kiesslich T, Lax S, Jahn S, Deutsch A,
Bauernhofer T, Ling H, et al: MiR-96-5p influences cellular growth
and is associated with poor survival in colorectal cancer patients.
Mol Carcinog. 54:1442–1450. 2015.PubMed/NCBI View
Article : Google Scholar
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Wu J, Wang F, Liu X, Zhang T, Liu F, Ge X,
Mao Y and Hua D: Correlation of IDH1 and B7H3 expression with
prognosis of CRC patients. Eur J Surg Oncol. 44:1254–1260.
2018.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Fang L, Li H, Wang L, Hu J, Jin T, Wang J
and Yang BB: MicroRNA-17-5p promotes chemotherapeutic drug
resistance and tumour metastasis of colorectal cancer by repressing
PTEN expression. Oncotarget. 5:2974–2987. 2014.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Zhang JR, Zhu RH and Han XP: MiR-410
affects the proliferation and apoptosis of lung cancer A549 cells
through regulation of SOCS3/JAK-STAT signaling pathway. Eur Rev Med
Pharmacol Sci. 22:5994–6001. 2018.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Jiang QQ and Liu WB: miR-25 promotes
melanoma progression by regulating RNA binding motif protein 47.
Med Sci (Paris). 34 Focus issue F1:59–65. 2018.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Guo Y, Pang Y, Gao X, Zhao M, Zhang X,
Zhang H, Xuan B and Wang Y: MicroRNA-137 chemosensitizes colon
cancer cells to the chemotherapeutic drug oxaliplatin (OXA) by
targeting YBX1. Cancer Biomark. 18:1–9. 2017.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Mlakar V, Berginc G, Volavsek M, Stor Z,
Rems M and Glavac D: Presence of activating KRAS mutations
correlates significantly with expression of tumour suppressor genes
DCN and TPM1 in colorectal cancer. BMC Cancer.
9(282)2009.PubMed/NCBI View Article : Google Scholar
|
